The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Nov. 03, 2020

Filed:

Feb. 29, 2016
Applicant:

Valencia Technologies Corporation, Valencia, CA (US);

Inventor:

David K. L. Peterson, Valencia, CA (US);

Assignee:
Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61B 5/00 (2006.01); A61B 5/021 (2006.01); A61N 1/36 (2006.01); A61N 1/05 (2006.01); G16H 50/30 (2018.01); G16H 20/40 (2018.01); G16H 20/10 (2018.01);
U.S. Cl.
CPC ...
A61B 5/7275 (2013.01); A61B 5/021 (2013.01); A61B 5/7246 (2013.01); A61N 1/0504 (2013.01); A61N 1/36117 (2013.01); G16H 20/40 (2018.01); G16H 50/30 (2018.01); G16H 20/10 (2018.01);
Abstract

An exemplary method includes determining a variability of a plurality of measurements of a cardiovascular parameter of a patient suffering from hypertension, the plurality of measurements recorded one at a time over a predetermined time period. The method further includes comparing the determined variability with a predetermined reference value. If the comparing indicates that the determined variability is less than the predetermined reference value, the method includes designating the patient to be within a first class of patients representative of patients that are likely to be responsive to subcutaneous neuromodulation therapy as a treatment for hypertension. If the comparing indicates that the determined variability is greater than the predetermined reference value, the method includes designating the patient to be within a second class of patients representative of patients that are likely to be unresponsive to subcutaneous neuromodulation therapy as a treatment for hypertension. Corresponding systems and methods are also described.


Find Patent Forward Citations

Loading…